Navigation Links
BiologicsMD, Inc. Announces Issuance of First U.S. Patent for PTH-CBD™
Date:8/15/2013

Fayetteville, Arkansas (PRWEB) August 15, 2013

BiologicsMD, Inc., a privately held drug discovery company developing unique biologic therapeutics for improving bone health, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,450,273, entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone," to The Board of Trustees of the University of Arkansas (U.S.), the Oschner Clinic Foundation (U.S.) and the National University Corporation Kagawa University (Japan). BiologicsMD™ is the exclusive licensee of the patent. The patent claims various forms of composition of matter for the proteins derived by the fusion between collagen-binding polypeptides bound to parathyroid hormone receptor agonists.

BiologicsMD is developing PTH-CBD™ as a novel and unique treatment for osteoporosis and other bone-related disorders. The technology originated in the laboratories of Joshua Sakon, Ph.D. (University Of Arkansas), Robert Gensure, M.D., Ph.D. (previously with the Oschner Clinic and currently with Montefiore Medical Center, NYC) and Osamu Matsushita, Ph.D. (previously with Kagawa University and currently with Okayama University).

"This is the first U.S. patent to issue from a patent family related to PTH-CBD and its use in treating diseases of the bone and other collagen-related disorders," stated J. David Owens, Chief Executive Officer of BiologicsMD. "PTH-CBD has pending methods patent applications in the U.S., along with patents being pursued in major worldwide markets. Because of PTH-CBD’s unique profile of selective targeting and other pharmacologic properties, we foresee a highly differentiated new product to help treat human disease.”

BiologicsMD, Inc. is an early stage therapeutics company that focuses on novel technologies to actively improve bone health. The company has an exclusive license to develop a new biologic therapeutic, PTH-CBD™, a molecular fusion of PTH (1-33) with the Collagen Binding Domain (CBD) of ColH collagenase. The CBD selectively binds to type I collagen, thus delivering PTH directly to the bone, where it can be most effective in building new bone. This CBD-derived targeting also provides for a long-acting therapeutic, thereby enabling semi-annual dosing for chronic disorders. The company was founded in 2010 and to date, the company has both raised private equity and has been awarded a $2.3 million research contract from the Department of Defense. BiologicsMD™ is a VIC Technology Venture Development™ portfolio company.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11030677.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Micropharma Limited announces new agreement to commercialize novel natural health products
2. Intrexon Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
3. WuXi PharmaTech Announces Second-Quarter 2013 Results
4. Charm Sciences, Inc. Announces Charm® FAST PHAGE Method Accepted by EPA for Detection of Coliphage in Ground Water
5. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vical Incorporated
6. BCA Announces a New Member Joins Its Blood Center Coperative
7. BioLife Solutions Announces Record Revenue of $2.3 Million in the Second Quarter of 2013
8. Mucosis Announces Publication of Data Demonstrating Safety and Protection by Mucosally Administered Mimopath®-based Prefusion-like F RSV Vaccines
9. Vivid Learning Systems Announces Newly Designed Industry Websites for MSHA, Electrical Utility Safety, Healthcare and OSHA Compliance
10. Nanounity Announces That the Delmic SECOM Correlative Microscopy System Has Won a 2013 Microscopy Today Innovation Award.
11. Natural Acne Remedy, Probiotic Action, Announces the Unveiling of their New Probiotic Acne Cleanser
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):